Pacific Biosciences of California (PACB)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $611.98M
Last updated: Nov 17, 2026 at 11:06 AM ET
Pacific Biosciences of California (PACB) Earnings: Report Dates and Results
Pacific Biosciences of California (PACB) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, Pacific Biosciences of California reported EPS of -$0.11, above the -$0.13 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PACB has an expected report date of Feb 9, 2027.
PACB Earnings Call
The latest PACB earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, PACB beat 18, missed 13 and matched 9. Revenue for the quarter ended Sep 30, 2026 was $40.56M, up 5.5% from $38.44M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.11 | -$0.13 | -$0.14 - -$0.12 | +15.38% | Beat | N/A | 7 | 0 up, 1 down | Nov 4, 2026 | $40.56M |
| Jun 30, 2026 | -$0.14 | -$0.14 | -$0.14 - -$0.12 | 0.00% | In line | N/A | 5 | 2 up, 1 down | Aug 3, 2026 | $39.01M |
| Mar 31, 2026 | -$0.12 | -$0.13 | -$0.17 - -$0.11 | +7.69% | Beat | N/A | 7 | 0 up, 1 down | May 7, 2026 | $37.18M |
| Dec 31, 2025 | -$0.12 | -$0.13 | -$0.15 - -$0.12 | +7.69% | Beat | N/A | 8 | 0 up, 1 down | Feb 12, 2026 | $44.65M |
| Sep 30, 2025 | -$0.12 | -$0.16 | -$0.16 - -$0.12 | +25.00% | Beat | N/A | 7 | 6 up, 0 down | Nov 5, 2025 | $38.44M |
| Jun 30, 2025 | -$0.13 | -$0.18 | -$0.18 - -$0.14 | +27.78% | Beat | N/A | 9 | 2 up, 0 down | Aug 7, 2025 | $39.77M |
| Mar 31, 2025 | -$0.15 | -$0.19 | -$0.20 - -$0.17 | +21.05% | Beat | N/A | 10 | 1 up, 2 down | May 8, 2025 | $37.15M |
| Dec 31, 2024 | -$0.20 | -$0.17 | -$0.21 - -$0.11 | -17.65% | Miss | N/A | 10 | 1 up, 1 down | Feb 13, 2025 | $39.22M |
| Sep 30, 2024 | -$0.17 | -$0.21 | -$0.30 - -$0.16 | +19.05% | Beat | N/A | 12 | 1 up, 0 down | Nov 7, 2024 | $39.97M |
| Jun 30, 2024 | -$0.20 | -$0.22 | -$0.29 - -$0.19 | +9.09% | Beat | N/A | 13 | 0 up, 0 down | Aug 7, 2024 | $36.01M |
| Mar 31, 2024 | -$0.26 | -$0.26 | -$0.32 - -$0.23 | 0.00% | In line | N/A | 13 | 4 up, 0 down | May 9, 2024 | $38.81M |
| Dec 31, 2023 | -$0.27 | -$0.28 | -$0.35 - -$0.24 | +3.57% | Beat | N/A | 15 | 2 up, 1 down | Feb 15, 2024 | $58.36M |
| Sep 30, 2023 | -$0.27 | -$0.29 | -$0.66 - -$0.26 | +6.90% | Beat | N/A | 10 | 2 up, 0 down | Oct 30, 2023 | $55.69M |
| Jun 30, 2023 | -$0.26 | -$0.31 | -$0.36 - -$0.29 | +16.13% | Beat | N/A | 11 | 0 up, 0 down | Aug 2, 2023 | $47.57M |
| Mar 31, 2023 | -$0.31 | -$0.33 | -$0.39 - -$0.29 | +6.06% | Beat | N/A | 8 | 0 up, 0 down | May 2, 2023 | $38.90M |
| Dec 31, 2022 | -$0.37 | -$0.36 | -$0.40 - -$0.34 | -2.78% | Miss | N/A | 8 | 0 up, 0 down | Feb 16, 2023 | $27.35M |
| Sep 30, 2022 | -$0.32 | -$0.33 | -$0.36 - -$0.31 | +3.03% | Beat | N/A | 6 | 0 up, 0 down | Nov 7, 2022 | $32.31M |
| Jun 30, 2022 | -$0.34 | -$0.34 | -$0.37 - -$0.24 | 0.00% | In line | N/A | 6 | 2 up, 0 down | Aug 3, 2022 | $35.47M |
| Mar 31, 2022 | -$0.37 | -$0.32 | -$0.33 - -$0.22 | -15.63% | Miss | N/A | 6 | 0 up, 0 down | May 4, 2022 | $33.17M |
| Dec 31, 2021 | -$0.30 | -$0.29 | -$0.29 - -$0.28 | -3.45% | Miss | N/A | 6 | N/A | Feb 15, 2022 | $36.02M |
| Sep 30, 2021 | -$0.23 | -$0.24 | -$0.24 - -$0.21 | +4.17% | Beat | N/A | 4 | N/A | Nov 2, 2021 | $34.89M |
| Jun 30, 2021 | -$0.21 | -$0.21 | -$0.22 - -$0.18 | 0.00% | In line | N/A | 5 | N/A | Aug 3, 2021 | $30.61M |
| Mar 31, 2021 | -$0.45 | -$0.31 | N/A | -45.16% | Miss | N/A | 5 | N/A | Apr 29, 2021 | $29.00M |
| Dec 31, 2020 | -$0.12 | -$0.12 | -$0.13 - $0.45 | 0.00% | In line | N/A | 5 | N/A | Feb 10, 2021 | $27.14M |
| Sep 30, 2020 | -$0.14 | -$0.13 | -$0.15 - -$0.13 | -7.69% | Miss | N/A | 5 | N/A | Nov 2, 2020 | $19.08M |
| Jun 30, 2020 | -$0.15 | -$0.18 | -$0.23 - -$0.14 | +16.67% | Beat | N/A | 3 | N/A | Aug 3, 2020 | $17.08M |
| Mar 31, 2020 | -$0.21 | -$0.15 | -$0.18 - -$0.14 | -40.00% | Miss | N/A | 4 | N/A | May 6, 2020 | $15.60M |
| Dec 31, 2019 | -$0.11 | -$0.14 | -$0.18 - -$0.14 | +21.43% | Beat | N/A | 3 | N/A | Feb 6, 2020 | $27.93M |
| Sep 30, 2019 | -$0.17 | -$0.15 | -$0.17 - -$0.13 | -13.33% | Miss | N/A | 4 | N/A | Nov 7, 2019 | $21.91M |
| Jun 30, 2019 | -$0.14 | -$0.14 | -$0.19 - -$0.12 | 0.00% | In line | N/A | 4 | N/A | Aug 6, 2019 | $24.62M |
| Mar 31, 2019 | -$0.16 | -$0.16 | -$0.20 - -$0.13 | 0.00% | In line | N/A | 5 | N/A | May 3, 2019 | $16.43M |
| Dec 31, 2018 | -$0.21 | -$0.13 | -$0.15 - -$0.12 | -61.54% | Miss | N/A | 5 | N/A | Feb 11, 2019 | $19.53M |
| Sep 30, 2018 | -$0.19 | -$0.15 | -$0.17 - -$0.13 | -26.67% | Miss | N/A | 7 | N/A | Nov 1, 2018 | $18.16M |
| Jun 30, 2018 | -$0.17 | -$0.17 | -$0.18 - -$0.15 | 0.00% | In line | N/A | 5 | N/A | Aug 2, 2018 | $21.58M |
| Mar 31, 2018 | -$0.20 | -$0.19 | -$0.20 - -$0.18 | -5.26% | Miss | N/A | 6 | N/A | May 2, 2018 | $19.36M |
| Dec 31, 2017 | -$0.18 | -$0.20 | -$0.21 - -$0.18 | +10.00% | Beat | N/A | 6 | N/A | Feb 1, 2018 | $24.93M |
| Sep 30, 2017 | -$0.19 | -$0.19 | -$0.23 - -$0.18 | 0.00% | In line | N/A | 6 | N/A | Nov 2, 2017 | $23.55M |
| Jun 30, 2017 | -$0.26 | -$0.24 | -$0.26 - -$0.22 | -8.33% | Miss | N/A | 6 | N/A | Aug 2, 2017 | $20.07M |
| Mar 31, 2017 | -$0.26 | -$0.23 | N/A | -13.04% | Miss | N/A | N/A | N/A | Apr 26, 2017 | $24.91M |
| Dec 31, 2016 | -$0.21 | -$0.23 | N/A | +8.70% | Beat | N/A | N/A | N/A | Feb 2, 2017 | $25.72M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.52, after -$0.83 the year before. It was -$0.84 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.52 | N/A |
| Dec 31, 2024 | -$0.83 | N/A |
| Dec 31, 2023 | -$1.11 | N/A |
| Dec 31, 2022 | -$1.40 | N/A |
| Dec 31, 2021 | -$1.19 | N/A |
| Dec 31, 2020 | -$0.62 | N/A |
| Dec 31, 2019 | -$0.58 | N/A |
| Dec 31, 2018 | -$0.77 | N/A |
| Dec 31, 2017 | -$0.89 | N/A |
| Dec 31, 2016 | -$0.84 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,600 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,612 | 9 | |
| 2026Q2 | Jun 30, 2026 | 6,443 | 13 | |
| 2026Q1 | Mar 31, 2026 | 5,745 | 9 | |
| 2025Q4 | Dec 31, 2025 | 9,189 | 12 | |
| 2025Q3 | Sep 30, 2025 | 6,332 | 12 | |
| 2025Q2 | Jun 30, 2025 | 6,974 | 12 | |
| 2025Q1 | Mar 31, 2025 | 2,621 | 9 | |
| 2024Q4 | Dec 31, 2024 | 5,214 | 11 |
2026Q3 Earnings Call
Opening remarks
Marissa Bych Investor Relations Good afternoon, and welcome to PacBio's third quarter 2026 earnings conference call. With me today are Mark Van Oene, President and Chief Executive Officer; and Bill Meyer, Chief Accounting Officer. Earlier today, we issued a press release outlining the financial results we'll be discussing on today's call, a copy of which is available on the Investors section of our website at www.pacb.com or as furnished on Form 8-K available on the Securities and Exchange Commission website, www.sec.gov. A copy of our earnings presentation is also available on the Investors section of our website. On today's call, we will make forward-looking statements, including, among others, statements providing predictions, estimates, expectations, and guidance. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual results to differ materially from those projected or discussed. Please review our SEC filings, including our most recent Form 10-Q and 10-K and our press release, to better understand the risks and uncertainties that could cause results to differ. We disclaim any obligation to update or revise these forward-looking statements, except as required by law. We also present certain financial information on a non-GAAP basis, which is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company's operating results as reported under U.S. GAAP. Reconciliations between historical U.S. GAAP and non-GAAP results are presented in our earnings release, which is available on the Investors section of our website. For future periods, we're unable to reconcile non-GAAP gross margin and non-GAAP operating expenses without unreasonable effort because certain items that impact these measures, including restructuring and related charges, settlement charges, and costs related to the disposition of short-read assets, are out of our control or cannot be reasonably predicted at this time, and their probable significance cannot be determined. A recording of today's call will be available shortly after the live call in the Investors section of our website. Those electing to use the replay are cautioned that forward-looking statements may differ or change materially after the completion of the live call. And with that, I will turn the call over to Mark.
Mark Van Oene President and CEO Thank you, and good afternoon, everyone. In the third quarter, we continued the launch of SPRQ-Nx chemistry. Over half of Revio consumable revenue came from customers using SPRQ-Nx. By quarter-end, two-thirds of our Revio installed base had opted to upgrade their software. Adoption continues to climb globally, and we expect the vast majority of the installed base to opt in by year-end. SPRQ-Nx is also driving higher utilization. Some customers are running the same pool of samples three times.
Frequently Asked Questions About PACB
When is Pacific Biosciences of California's next earnings date?
Pacific Biosciences of California's next earnings report is expected for Feb 9, 2027.
Did PACB beat earnings estimates last quarter?
Yes. Pacific Biosciences of California reported EPS of -$0.11 for the quarter ended Sep 30, 2026, above the -$0.13 estimate, a 15.38% surprise.
What EPS do analysts expect from PACB next quarter?
The consensus EPS estimate for Pacific Biosciences of California for the quarter ending Dec 31, 2026 is -$0.13 from 10 analysts, with estimates from -$0.13 to -$0.11.
How often does PACB beat earnings estimates?
Pacific Biosciences of California beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +10.87%.
PACB pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts